Senseonics Holdings, Inc. reports developments tied to its long-term, implantable continuous glucose monitoring systems for people with diabetes. The company designs, develops, manufactures and commercializes the Eversense CGM platform, including Eversense 365 and Eversense E3, which use an under-the-skin sensor, a wearable smart transmitter and a mobile app for glucose data.
Recurring news for SENS covers financial results, U.S. and European commercialization, CE Mark and product-launch activity, automated insulin delivery integrations, and pipeline work on Gemini and Freedom systems. Company updates also include capital actions such as common stock and pre-funded warrant offerings, loan-facility amendments, and funding for Eversense 365 commercialization and product development.
Senseonics Holdings, a medical technology firm specializing in long-term, implantable continuous glucose monitoring (CGM) systems, reported its Q1 2024 financial results.
The company achieved $5.1 million in revenue, a 22% increase compared to Q1 2023. However, gross profit declined to $0.3 million due to higher fixed manufacturing costs.
Notable achievements include the integration of Eversense CGM with Mercy health system, the FDA iCGM designation for Eversense, and the filing for the next-generation 365-day system.
Despite these advancements, the firm posted a net loss of $18.9 million, or $0.03 per share, significantly down from a $1.3 million net income in Q1 2023. First half 2024 revenue is projected at $10 million, a 16% growth year-over-year.
Senseonics (NYSE American: SENS) has announced a partnership with Mercy, a prominent health care system, to enhance diabetes population health management. This collaboration will utilize Senseonics' Eversense implantable continuous glucose monitor (CGM) technology and the new Eversense Remote Patient Monitoring (RPM) solution across Mercy's extensive network. Mercy, serving over 3 million patients annually, plans to implement the program in phases starting July, initially targeting 30,000 patients. This initiative aims to improve patient care, reduce hospitalizations, and provide personalized diabetes management, reaching full implementation by 2025.
Senseonics Holdings, Inc. (NYSE American: SENS) partners with Rimidi to develop the Eversense CGM+RPM solution, integrating glucose data into Rimidi's clinical management platform for diabetes management. The program aims to optimize care, improve patient outcomes, and reduce healthcare costs. The collaboration will offer a comprehensive diabetes solution, combining long-term implantable CGM technology with analytics and personalized health services.
Senseonics Holdings, Inc. (NYSE American: SENS) will be participating in two upcoming conferences: the RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York, NY. Management will engage in one-on-one meetings at both events, with the RBC conference scheduled for May 15, 2024, and the H.C. Wainwright conference on May 20, 2024. A live and recorded webcast of the presentation will be available on the 'Investor Relations' section of the company's website.
Senseonics Holdings, Inc. (NYSE American: SENS) is set to release its first quarter 2024 financial results on May 13, 2024, after the market closes. The company specializes in the development of long-term, implantable continuous glucose monitoring systems for individuals with diabetes. A conference call to discuss the performance is scheduled for 4:30 p.m. (Eastern Time) on the same day.
The Eversense® CGM System by Senseonics Holdings, Inc. has received an integrated CGM (iCGM) designation by the US FDA, allowing integration with insulin pumps for an automated insulin delivery system. Eversense is the first fully implantable device in its category with iCGM status, offering new interoperable CGM options. The partnership with Ascensia Diabetes Care aims to provide diabetes patients with advanced technology meeting high standards for accuracy, alert detection, and wear time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.